Please find our unchanged analysis here.

As the market becomes increasingly comfortable with the size and shape of Teva’s forthcoming opioid settlements, analysts are beginning to return their attention to

Please find our updated analysis on Teva here.
We exited our long position in August 2020 after a successful trade, but have now re-examined Teva from a

Please refer to our unchanged analysis here.
Operationally there are limited concerns, but any change in approach from

We have updated our model here

We exited our position in the Euro 27;s in mid August and despite the

We are exiting our long position in the Euro 27’s, as with everything in the Teva structure trading tighter than 5% we question the further upside in the position. This trade has been a successful position for us, entering the 27’s in the low 70’s, the time has come for us to exit.

Very confident and nearly bullish call from TEVA management on the release of their Q1 results. Leverage

Please find our updated Teva model here.

Following price movements over the last month, we are unwinding our Teva

Teva results are out, conference call at 1pm. Results are inline to slight beat to previous

Overall the results are stronger than we were expecting.

Results:

Decline in Copaxone and stronger growth in Ajovy helped with both top line and

Clarified from the Company that the RCF will become senior secured if over $1bn of senior bonds are issued. There is NO LIMIT on the amount of

Please find our updated analysis and model here.

We have become to build a position, long 2027’s and short 2020’a Euro bonds, with a view to benefiting from an early settlement of the opioid litigation, while protecting